🔗 Share this article

An underground economy for unapproved slimming drugs is being driven by social media fitness personalities and sellers on messaging platforms, based on recent findings.

Investigational Treatment Acquiring Traction Online

The experimental drug, which remains in clinical trials, is being advertised by social media influencers for its supposed fat-burning properties. Followers are encouraged to message these profiles privately for source information, while also receiving discount codes.

Active Commerce on Social Networks

Separately, a robust market exists on messaging services, where communities with numerous of participants share “before and after” images, administration instructions and claims of next-day UK delivery. Vendors promote the substance there before directing customers to other platforms for purchases.

Understanding The Experimental Drug

This medication is an investigational injectable created by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could assist patients lose up to 25% of their total weight. Nicknamed the “triple G”, the drug is being hailed online as the successor to Ozempic.

Healthcare Experts Express Concerns

Nevertheless, doctors and pharmacists have cautions that the distribution of what is still an unapproved medication in the United Kingdom is a cause for concern and could lead to users injecting products of uncertain source.

Several experts said the demand for retatrutide could be connected to the rising cost of approved weight loss products such as Mounjaro.

Legal Position and Enforcement

Selling retatrutide on TikTok or messaging apps is prohibited in the UK, as it is an unlicensed medication that cannot be marketed or distributed for human use under the Human Medicines Regulations 2012.

Some influencers attempt to circumvent the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled substance, but promotion and supply can still violate pharmaceutical, marketing, and consumer regulations, potentially leading to penalties, prosecution or imprisonment.

Platform Response and Content Elimination

According to the social media company, the service has removed violative content and banned related hashtags and query recommendations. The company stated it was dedicated to maintaining the platform safe and allocating resources in enhancing enforcement strategies.

Digital Marketplace Operations

Investigations also found communities with up to nine thousand members selling retatrutide using the platform's built-in discovery tool, which operates like a online catalog. Entering “retatrutide” instantly displays channels with numerous of users, filled with images of weight loss, positive reviews and detailed guides for preparing or injecting at home.

Within moments of entering one community, a vendor posted WhatsApp details, where the majority of transactions occur. The seller provided an instruction manual and promised shipping within two days. When questioned whether the product was genuine, one vendor responded: “You can’t be sure.” Another shared a photo of a alleged testing documentation. Not one inquired about body mass, medical conditions or previous experience.

Item Information and Pricing

Within these groups, messages display black plastic packages with postal service stickers, stating to include new batches. One communication stated: “It took eight of us to load them this morning.”

Buyers can select between powder vials, mixed at home with purified liquid, or ready-to-use injectors usually sold at 160 pounds for 20mg. When questioned how much time a injector should be used, sellers give conflicting responses varying between a few weeks to “depends on your body”.

Service Oversight and Security Actions

A spokesperson for Telegram stated it actively moderated dangerous material on its platform including material that encouraged the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are administering materials they cannot confirm. Even if the research behind retatrutide is valid, these online products may not include what they claim,” stated Jason Murphy, the head of pharmaceutical services at a pharmacy service.

A medical professional of an online medical service connected the increase in demand to recent cost increases for approved weight-loss medications such as Mounjaro. “With prices rising, patients are using online platforms. But fake treatments are highly dangerous. You can’t be certain what’s contained or whether the conditions they were made in was clean,” she said.

Her team has previously encountered patients injured by personal administration from unconfirmed sources. “We understand the frustration, but buying from messaging apps or WhatsApp is gambling with your well-being,” said the doctor. “These substances could be impure or improperly measured.”

Manufacturer Position

A spokesperson from Eli Lilly said retatrutide was in third stage research studies and had not been reviewed or authorized by any regulatory agency globally. “Therefore at this time no one can sell [it] for personal consumption,” they explained, adding that any item “falsely representing itself as a company investigational substance not yet authorized … may subject patients to potentially serious health risks”.